Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
More News
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
Zacks
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
Zacks
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
Key PointsSold 228,895 shares of ANI Pharmaceuticals; estimated trade value $17.87 million (based on average Q1 2026 pricing...
Nasdaq News: Markets
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
Zacks
Zacks.com featured highlights include ANI, Cummins and Seadrill
ANI, Cummins and Seadrill have been highlighted in this Screen of The Week article.
Zacks
3 Stocks Showing Powerful Earnings Acceleration This May
ANIP, CMI and SDRL stand out in May as earnings acceleration stocks, with rising EPS growth trends signaling potential share price momentum.
Zacks
ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.